| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 230 | 2024 | 5351 | 10.210 |
Why?
|
| Pancreaticoduodenectomy | 111 | 2024 | 508 | 10.150 |
Why?
|
| Pancreatectomy | 87 | 2023 | 810 | 7.930 |
Why?
|
| Carcinoma, Pancreatic Ductal | 96 | 2024 | 1724 | 7.020 |
Why?
|
| General Surgery | 35 | 2024 | 1678 | 4.190 |
Why?
|
| Pancreatic Fistula | 26 | 2022 | 148 | 3.530 |
Why?
|
| Adenocarcinoma | 90 | 2023 | 6315 | 3.040 |
Why?
|
| Bile Ducts | 23 | 2020 | 282 | 2.670 |
Why?
|
| Adenocarcinoma, Mucinous | 24 | 2023 | 517 | 2.630 |
Why?
|
| Cholecystectomy, Laparoscopic | 22 | 2018 | 231 | 2.510 |
Why?
|
| Pancreas | 32 | 2023 | 1677 | 2.480 |
Why?
|
| Pancreatic Diseases | 19 | 2019 | 343 | 2.220 |
Why?
|
| Pancreatic Ducts | 17 | 2024 | 329 | 2.110 |
Why?
|
| Common Bile Duct Neoplasms | 24 | 2023 | 120 | 2.010 |
Why?
|
| Ampulla of Vater | 28 | 2023 | 149 | 1.990 |
Why?
|
| Pancreatitis, Acute Necrotizing | 10 | 2022 | 173 | 1.900 |
Why?
|
| Hepatectomy | 15 | 2020 | 559 | 1.840 |
Why?
|
| Carcinoma, Papillary | 17 | 2018 | 785 | 1.820 |
Why?
|
| Periodicals as Topic | 11 | 2022 | 1469 | 1.660 |
Why?
|
| Surgical Procedures, Operative | 16 | 2020 | 1913 | 1.630 |
Why?
|
| Bile Duct Diseases | 7 | 2020 | 97 | 1.620 |
Why?
|
| Pancreatitis | 17 | 2022 | 1100 | 1.570 |
Why?
|
| Pancreatic Cyst | 11 | 2024 | 367 | 1.420 |
Why?
|
| Bile | 25 | 2021 | 296 | 1.400 |
Why?
|
| Digestive System Surgical Procedures | 13 | 2021 | 575 | 1.370 |
Why?
|
| Cholelithiasis | 32 | 2017 | 408 | 1.350 |
Why?
|
| Cholecystectomy | 22 | 2020 | 406 | 1.300 |
Why?
|
| Neoadjuvant Therapy | 35 | 2024 | 2821 | 1.290 |
Why?
|
| Postoperative Complications | 71 | 2022 | 15697 | 1.270 |
Why?
|
| Bile Duct Neoplasms | 18 | 2019 | 602 | 1.250 |
Why?
|
| Portal Vein | 7 | 2023 | 429 | 1.210 |
Why?
|
| Societies, Medical | 9 | 2020 | 3905 | 1.140 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 7 | 2023 | 194 | 1.130 |
Why?
|
| Survival Rate | 83 | 2024 | 12808 | 1.040 |
Why?
|
| Clinical Competence | 23 | 2020 | 4783 | 1.040 |
Why?
|
| Humans | 541 | 2024 | 760621 | 1.030 |
Why?
|
| Neoplasm Staging | 44 | 2024 | 11152 | 0.990 |
Why?
|
| Pancreaticojejunostomy | 6 | 2020 | 26 | 0.990 |
Why?
|
| Palliative Care | 24 | 2019 | 3607 | 0.980 |
Why?
|
| Editorial Policies | 3 | 2021 | 457 | 0.980 |
Why?
|
| Duodenal Neoplasms | 18 | 2023 | 115 | 0.970 |
Why?
|
| Cholangiocarcinoma | 11 | 2019 | 550 | 0.970 |
Why?
|
| Intraoperative Complications | 17 | 2019 | 1186 | 0.960 |
Why?
|
| Sphincter of Oddi | 11 | 1999 | 21 | 0.890 |
Why?
|
| Liver Neoplasms | 13 | 2020 | 4319 | 0.880 |
Why?
|
| Diagnostic Imaging | 18 | 2000 | 3527 | 0.860 |
Why?
|
| Professional Autonomy | 7 | 2019 | 171 | 0.860 |
Why?
|
| Fluorouracil | 23 | 2023 | 1631 | 0.860 |
Why?
|
| Biliary Tract Surgical Procedures | 8 | 2018 | 45 | 0.860 |
Why?
|
| Laparoscopy | 18 | 2020 | 2147 | 0.830 |
Why?
|
| Male | 349 | 2024 | 359744 | 0.830 |
Why?
|
| Aged | 246 | 2024 | 169152 | 0.830 |
Why?
|
| Middle Aged | 274 | 2024 | 220352 | 0.820 |
Why?
|
| Retrospective Studies | 154 | 2024 | 80372 | 0.820 |
Why?
|
| Leadership | 5 | 2020 | 1371 | 0.820 |
Why?
|
| Neuroendocrine Tumors | 8 | 2022 | 650 | 0.780 |
Why?
|
| Female | 331 | 2024 | 391270 | 0.770 |
Why?
|
| Cholestasis | 15 | 2011 | 377 | 0.770 |
Why?
|
| Hepatic Duct, Common | 7 | 2011 | 48 | 0.760 |
Why?
|
| Hospitals, General | 6 | 2022 | 795 | 0.760 |
Why?
|
| Internship and Residency | 21 | 2024 | 5870 | 0.740 |
Why?
|
| Indiana | 12 | 2015 | 93 | 0.730 |
Why?
|
| Mesenteric Veins | 6 | 2023 | 85 | 0.710 |
Why?
|
| Gallbladder | 18 | 2006 | 305 | 0.690 |
Why?
|
| Pain, Postoperative | 2 | 2020 | 1721 | 0.680 |
Why?
|
| Bile Ducts, Intrahepatic | 7 | 2015 | 296 | 0.680 |
Why?
|
| CA-19-9 Antigen | 7 | 2022 | 106 | 0.660 |
Why?
|
| Leucovorin | 14 | 2023 | 641 | 0.650 |
Why?
|
| Drainage | 12 | 2022 | 1161 | 0.640 |
Why?
|
| Coronavirus Infections | 6 | 2020 | 3085 | 0.620 |
Why?
|
| Pneumonia, Viral | 6 | 2020 | 3205 | 0.610 |
Why?
|
| Patient Readmission | 13 | 2023 | 3323 | 0.610 |
Why?
|
| Endosonography | 6 | 2011 | 607 | 0.600 |
Why?
|
| Preoperative Care | 15 | 2019 | 2256 | 0.600 |
Why?
|
| Education, Medical | 3 | 2019 | 1727 | 0.580 |
Why?
|
| Neoplasm Invasiveness | 18 | 2021 | 3618 | 0.580 |
Why?
|
| Cholecystitis | 6 | 2000 | 181 | 0.580 |
Why?
|
| Prognosis | 62 | 2023 | 29658 | 0.580 |
Why?
|
| Biomedical Research | 5 | 2022 | 3426 | 0.580 |
Why?
|
| Mentors | 4 | 2018 | 661 | 0.560 |
Why?
|
| Inappropriate Prescribing | 1 | 2019 | 209 | 0.550 |
Why?
|
| Length of Stay | 29 | 2022 | 6479 | 0.550 |
Why?
|
| Social Justice | 2 | 2020 | 479 | 0.540 |
Why?
|
| Adult | 174 | 2024 | 219994 | 0.540 |
Why?
|
| Morbidity | 8 | 2017 | 1765 | 0.540 |
Why?
|
| Hospitals, Teaching | 2 | 2018 | 1166 | 0.530 |
Why?
|
| Lymph Node Excision | 11 | 2024 | 1303 | 0.530 |
Why?
|
| Anastomosis, Surgical | 13 | 2024 | 983 | 0.520 |
Why?
|
| Dissent and Disputes | 1 | 2017 | 146 | 0.510 |
Why?
|
| Lymph Nodes | 15 | 2024 | 3486 | 0.510 |
Why?
|
| Patient Care Team | 6 | 2024 | 2511 | 0.510 |
Why?
|
| Aged, 80 and over | 97 | 2024 | 58995 | 0.510 |
Why?
|
| Treatment Outcome | 92 | 2023 | 65017 | 0.500 |
Why?
|
| Stents | 18 | 2018 | 3314 | 0.500 |
Why?
|
| Survival Analysis | 35 | 2021 | 10182 | 0.490 |
Why?
|
| Interprofessional Relations | 7 | 2019 | 989 | 0.490 |
Why?
|
| Blood Loss, Surgical | 8 | 2023 | 656 | 0.490 |
Why?
|
| Education, Medical, Graduate | 6 | 2024 | 2363 | 0.490 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2020 | 951 | 0.490 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 25 | 2023 | 11712 | 0.480 |
Why?
|
| Hospitals, University | 5 | 2010 | 568 | 0.470 |
Why?
|
| Iatrogenic Disease | 1 | 2018 | 538 | 0.470 |
Why?
|
| Specialties, Surgical | 5 | 2018 | 388 | 0.470 |
Why?
|
| Liver Abscess, Pyogenic | 1 | 2014 | 7 | 0.470 |
Why?
|
| Bile Ducts, Extrahepatic | 4 | 2004 | 49 | 0.470 |
Why?
|
| Intestinal Obstruction | 7 | 2020 | 434 | 0.470 |
Why?
|
| Pandemics | 9 | 2023 | 8624 | 0.460 |
Why?
|
| Cholangiography | 9 | 2011 | 181 | 0.460 |
Why?
|
| Drug Prescriptions | 2 | 2020 | 1673 | 0.460 |
Why?
|
| Intestine, Small | 8 | 2020 | 1207 | 0.460 |
Why?
|
| Abdominal Pain | 6 | 2015 | 1063 | 0.460 |
Why?
|
| Culture | 1 | 2018 | 622 | 0.460 |
Why?
|
| Biliary Fistula | 1 | 2014 | 37 | 0.460 |
Why?
|
| Neoplasm Recurrence, Local | 20 | 2023 | 9276 | 0.460 |
Why?
|
| Practice Guidelines as Topic | 9 | 2021 | 7475 | 0.450 |
Why?
|
| Analgesics, Opioid | 2 | 2020 | 3763 | 0.450 |
Why?
|
| Lymphatic Metastasis | 24 | 2024 | 2943 | 0.450 |
Why?
|
| Surgical Wound Infection | 7 | 2018 | 1527 | 0.450 |
Why?
|
| Academic Medical Centers | 7 | 2024 | 2754 | 0.440 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 934 | 0.440 |
Why?
|
| Tomography, X-Ray Computed | 34 | 2019 | 20509 | 0.440 |
Why?
|
| Cholangitis | 5 | 2020 | 113 | 0.440 |
Why?
|
| Intraoperative Care | 6 | 2019 | 768 | 0.440 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 4 | 2011 | 100 | 0.440 |
Why?
|
| Opioid-Related Disorders | 2 | 2019 | 2138 | 0.440 |
Why?
|
| Disease-Free Survival | 22 | 2024 | 6828 | 0.430 |
Why?
|
| Robotics | 3 | 2018 | 874 | 0.430 |
Why?
|
| Health Status Indicators | 3 | 2017 | 968 | 0.430 |
Why?
|
| Follow-Up Studies | 58 | 2021 | 39261 | 0.420 |
Why?
|
| Career Choice | 2 | 2014 | 754 | 0.420 |
Why?
|
| Sciuridae | 18 | 1998 | 78 | 0.420 |
Why?
|
| Program Evaluation | 5 | 2024 | 2493 | 0.410 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 10 | 2014 | 506 | 0.390 |
Why?
|
| Kaplan-Meier Estimate | 19 | 2021 | 6544 | 0.380 |
Why?
|
| Baltimore | 5 | 2018 | 230 | 0.380 |
Why?
|
| United States | 48 | 2023 | 72461 | 0.380 |
Why?
|
| Decision Support Techniques | 4 | 2018 | 2001 | 0.370 |
Why?
|
| Omentum | 1 | 2012 | 169 | 0.370 |
Why?
|
| Jejunostomy | 5 | 2010 | 59 | 0.370 |
Why?
|
| Chemotherapy, Adjuvant | 22 | 2024 | 3529 | 0.370 |
Why?
|
| Debridement | 4 | 2020 | 492 | 0.370 |
Why?
|
| Splenic Artery | 1 | 2011 | 57 | 0.370 |
Why?
|
| Malpractice | 3 | 2021 | 556 | 0.360 |
Why?
|
| Sex Factors | 10 | 2022 | 10547 | 0.360 |
Why?
|
| Adenocarcinoma, Papillary | 3 | 2021 | 84 | 0.360 |
Why?
|
| Anti-Bacterial Agents | 7 | 2021 | 7408 | 0.350 |
Why?
|
| Forecasting | 2 | 2017 | 2932 | 0.350 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2019 | 2299 | 0.350 |
Why?
|
| Catheterization | 8 | 2005 | 1432 | 0.350 |
Why?
|
| Biopsy, Fine-Needle | 4 | 2014 | 1110 | 0.350 |
Why?
|
| Hemostasis, Surgical | 1 | 2010 | 129 | 0.340 |
Why?
|
| Hepatic Artery | 3 | 2024 | 230 | 0.340 |
Why?
|
| Cancer Care Facilities | 3 | 2020 | 424 | 0.340 |
Why?
|
| Predictive Value of Tests | 28 | 2020 | 15289 | 0.340 |
Why?
|
| Abdomen, Acute | 2 | 2000 | 122 | 0.340 |
Why?
|
| Splenectomy | 1 | 2011 | 391 | 0.330 |
Why?
|
| Surgery Department, Hospital | 2 | 2020 | 177 | 0.330 |
Why?
|
| Risk Assessment | 25 | 2021 | 24123 | 0.320 |
Why?
|
| Education, Medical, Continuing | 1 | 2014 | 830 | 0.320 |
Why?
|
| Acute Disease | 14 | 2022 | 7269 | 0.310 |
Why?
|
| Deoxycytidine | 4 | 2020 | 873 | 0.300 |
Why?
|
| Gallbladder Diseases | 2 | 2019 | 137 | 0.300 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2009 | 138 | 0.300 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 1066 | 0.300 |
Why?
|
| Endoscopy | 4 | 2021 | 1838 | 0.300 |
Why?
|
| Equipment Failure | 1 | 2010 | 577 | 0.300 |
Why?
|
| Diagnosis, Differential | 23 | 2014 | 12965 | 0.290 |
Why?
|
| Liver Transplantation | 5 | 2017 | 2325 | 0.290 |
Why?
|
| Prospective Studies | 45 | 2024 | 54303 | 0.290 |
Why?
|
| Personnel Selection | 2 | 2020 | 193 | 0.290 |
Why?
|
| Camptothecin | 3 | 2017 | 590 | 0.290 |
Why?
|
| Cystadenoma, Serous | 3 | 2021 | 100 | 0.290 |
Why?
|
| Caregivers | 4 | 2023 | 2224 | 0.290 |
Why?
|
| Early Detection of Cancer | 3 | 2019 | 3202 | 0.280 |
Why?
|
| Risk Factors | 46 | 2023 | 74359 | 0.280 |
Why?
|
| Benchmarking | 3 | 2020 | 1044 | 0.280 |
Why?
|
| Acetamides | 2 | 2020 | 256 | 0.270 |
Why?
|
| Quality of Health Care | 4 | 2021 | 4360 | 0.270 |
Why?
|
| Biliary Tract Diseases | 2 | 2006 | 157 | 0.270 |
Why?
|
| Adipose Tissue | 2 | 2009 | 3301 | 0.270 |
Why?
|
| Azepines | 2 | 2020 | 330 | 0.270 |
Why?
|
| Massachusetts | 15 | 2020 | 8803 | 0.270 |
Why?
|
| Time Factors | 39 | 2021 | 40165 | 0.270 |
Why?
|
| Laparotomy | 3 | 2018 | 465 | 0.270 |
Why?
|
| Cultural Diversity | 2 | 2021 | 365 | 0.270 |
Why?
|
| Triage | 4 | 2021 | 987 | 0.260 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2015 | 586 | 0.260 |
Why?
|
| Sigmoid Diseases | 2 | 2010 | 59 | 0.260 |
Why?
|
| Gallbladder Neoplasms | 2 | 2007 | 190 | 0.260 |
Why?
|
| Cholangitis, Sclerosing | 6 | 1999 | 177 | 0.260 |
Why?
|
| Erythrocyte Transfusion | 1 | 2010 | 566 | 0.250 |
Why?
|
| Journal Impact Factor | 3 | 2023 | 156 | 0.250 |
Why?
|
| Cholestasis, Extrahepatic | 4 | 2000 | 51 | 0.250 |
Why?
|
| Quality of Life | 14 | 2023 | 13308 | 0.250 |
Why?
|
| Histiocytoma, Malignant Fibrous | 1 | 2005 | 55 | 0.250 |
Why?
|
| Statistics, Nonparametric | 6 | 2019 | 2852 | 0.250 |
Why?
|
| Physicians, Women | 2 | 2022 | 495 | 0.250 |
Why?
|
| Schools, Medical | 2 | 2016 | 878 | 0.250 |
Why?
|
| Multivariate Analysis | 18 | 2020 | 12159 | 0.250 |
Why?
|
| Precancerous Conditions | 5 | 2015 | 977 | 0.250 |
Why?
|
| Accreditation | 2 | 2020 | 477 | 0.240 |
Why?
|
| Mortality | 2 | 2016 | 2916 | 0.240 |
Why?
|
| Registries | 9 | 2023 | 8469 | 0.240 |
Why?
|
| Neoplastic Cells, Circulating | 3 | 2017 | 938 | 0.240 |
Why?
|
| Octreotide | 4 | 2011 | 153 | 0.240 |
Why?
|
| Dinoprostone | 1 | 2007 | 598 | 0.240 |
Why?
|
| Medical Errors | 3 | 2019 | 1255 | 0.240 |
Why?
|
| Gastrointestinal Motility | 4 | 1994 | 234 | 0.240 |
Why?
|
| Organoplatinum Compounds | 3 | 2017 | 410 | 0.240 |
Why?
|
| Fibrin Tissue Adhesive | 1 | 2004 | 86 | 0.230 |
Why?
|
| Attitude of Health Personnel | 6 | 2020 | 3865 | 0.230 |
Why?
|
| Cutaneous Fistula | 1 | 2004 | 79 | 0.230 |
Why?
|
| Emergencies | 5 | 2014 | 1211 | 0.230 |
Why?
|
| Pneumoperitoneum | 2 | 2021 | 46 | 0.230 |
Why?
|
| Gastrectomy | 6 | 2019 | 679 | 0.230 |
Why?
|
| Quality Indicators, Health Care | 3 | 2014 | 1824 | 0.230 |
Why?
|
| Physician's Role | 3 | 2020 | 918 | 0.230 |
Why?
|
| Tumor Microenvironment | 5 | 2021 | 3844 | 0.230 |
Why?
|
| Pancreatic Pseudocyst | 3 | 2006 | 110 | 0.230 |
Why?
|
| Cholesterol | 13 | 1997 | 2924 | 0.230 |
Why?
|
| Hyperamylasemia | 2 | 2022 | 6 | 0.220 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2020 | 2828 | 0.220 |
Why?
|
| Proportional Hazards Models | 18 | 2020 | 12531 | 0.220 |
Why?
|
| Hemorrhage | 3 | 2022 | 3600 | 0.220 |
Why?
|
| Pancreatitis, Chronic | 4 | 2020 | 281 | 0.220 |
Why?
|
| Constriction, Pathologic | 7 | 2010 | 1098 | 0.220 |
Why?
|
| Liver | 10 | 2014 | 7509 | 0.220 |
Why?
|
| Stomach Neoplasms | 6 | 2006 | 1423 | 0.220 |
Why?
|
| Quality Improvement | 5 | 2020 | 3836 | 0.210 |
Why?
|
| Bees | 1 | 2023 | 45 | 0.210 |
Why?
|
| Tissue Adhesives | 1 | 2004 | 173 | 0.210 |
Why?
|
| Ligation | 2 | 2016 | 448 | 0.210 |
Why?
|
| Nomograms | 3 | 2022 | 238 | 0.210 |
Why?
|
| Bilirubin | 8 | 1995 | 438 | 0.210 |
Why?
|
| Vascular Surgical Procedures | 3 | 2021 | 1475 | 0.210 |
Why?
|
| Duodenal Obstruction | 3 | 1998 | 25 | 0.200 |
Why?
|
| Hospital Mortality | 11 | 2021 | 5425 | 0.200 |
Why?
|
| Combined Modality Therapy | 18 | 2024 | 8552 | 0.200 |
Why?
|
| Vascular Neoplasms | 2 | 2009 | 167 | 0.200 |
Why?
|
| Cyst Fluid | 2 | 2021 | 83 | 0.200 |
Why?
|
| Faculty, Medical | 3 | 2022 | 1192 | 0.200 |
Why?
|
| Natural Language Processing | 2 | 2023 | 1135 | 0.200 |
Why?
|
| Radiation Dosage | 1 | 2010 | 1958 | 0.200 |
Why?
|
| Pancreatitis, Alcoholic | 2 | 1998 | 28 | 0.190 |
Why?
|
| Carcinoma, Acinar Cell | 3 | 2017 | 62 | 0.190 |
Why?
|
| Healthcare Disparities | 4 | 2023 | 3388 | 0.190 |
Why?
|
| Music | 2 | 2015 | 245 | 0.190 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2022 | 136 | 0.190 |
Why?
|
| Duodenum | 11 | 1998 | 486 | 0.190 |
Why?
|
| Operating Rooms | 2 | 2019 | 789 | 0.190 |
Why?
|
| Sexual Harassment | 2 | 2019 | 80 | 0.190 |
Why?
|
| Endoscopy, Digestive System | 4 | 2018 | 351 | 0.190 |
Why?
|
| Chi-Square Distribution | 7 | 2010 | 3465 | 0.180 |
Why?
|
| Specialization | 2 | 2017 | 778 | 0.180 |
Why?
|
| Learning | 1 | 2010 | 1739 | 0.180 |
Why?
|
| Neoplastic Stem Cells | 2 | 2020 | 1347 | 0.180 |
Why?
|
| Diabetes Mellitus | 6 | 2023 | 5889 | 0.180 |
Why?
|
| Authorship | 2 | 2022 | 281 | 0.180 |
Why?
|
| Otorhinolaryngologic Neoplasms | 1 | 2000 | 26 | 0.180 |
Why?
|
| Gastroenterology | 2 | 2013 | 571 | 0.180 |
Why?
|
| Radiology, Interventional | 2 | 2013 | 475 | 0.180 |
Why?
|
| Antineoplastic Agents | 7 | 2020 | 13630 | 0.180 |
Why?
|
| Decision Making | 6 | 2020 | 3925 | 0.180 |
Why?
|
| Piperidines | 1 | 2009 | 1650 | 0.180 |
Why?
|
| Bibliometrics | 2 | 2023 | 351 | 0.180 |
Why?
|
| Tissue Adhesions | 2 | 2020 | 222 | 0.180 |
Why?
|
| Comparative Effectiveness Research | 2 | 2024 | 718 | 0.180 |
Why?
|
| Wounds, Nonpenetrating | 2 | 2004 | 793 | 0.180 |
Why?
|
| Palpation | 1 | 2000 | 166 | 0.170 |
Why?
|
| Fever of Unknown Origin | 1 | 2000 | 94 | 0.170 |
Why?
|
| History, 20th Century | 5 | 2020 | 2773 | 0.170 |
Why?
|
| Klebsiella Infections | 1 | 2021 | 147 | 0.170 |
Why?
|
| Gastric Mucosa | 4 | 1983 | 599 | 0.170 |
Why?
|
| Publishing | 2 | 2020 | 836 | 0.170 |
Why?
|
| Professional Practice Location | 1 | 2020 | 56 | 0.170 |
Why?
|
| Gastrostomy | 3 | 1999 | 321 | 0.170 |
Why?
|
| Incidence | 17 | 2020 | 21392 | 0.170 |
Why?
|
| Adrenalectomy | 1 | 2001 | 348 | 0.170 |
Why?
|
| Parathyroidectomy | 1 | 2001 | 241 | 0.170 |
Why?
|
| Embolization, Therapeutic | 2 | 2022 | 1413 | 0.170 |
Why?
|
| Cohort Studies | 17 | 2022 | 41335 | 0.170 |
Why?
|
| Calcium | 10 | 1995 | 5725 | 0.170 |
Why?
|
| Cholecystokinin | 3 | 1997 | 117 | 0.170 |
Why?
|
| Video-Assisted Surgery | 1 | 2019 | 51 | 0.170 |
Why?
|
| Gastrointestinal Hemorrhage | 4 | 2011 | 1131 | 0.170 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2000 | 95 | 0.170 |
Why?
|
| Esophageal Achalasia | 1 | 2020 | 94 | 0.170 |
Why?
|
| Peer Review | 1 | 2021 | 218 | 0.160 |
Why?
|
| Intracranial Thrombosis | 1 | 2020 | 109 | 0.160 |
Why?
|
| Klebsiella pneumoniae | 1 | 2021 | 255 | 0.160 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2019 | 3804 | 0.160 |
Why?
|
| Antimetabolites, Antineoplastic | 4 | 2013 | 640 | 0.160 |
Why?
|
| Colorectal Neoplasms | 6 | 2020 | 6853 | 0.160 |
Why?
|
| Intraoperative Period | 6 | 2018 | 516 | 0.160 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2020 | 119 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2014 | 10344 | 0.160 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2005 | 615 | 0.160 |
Why?
|
| Gastrinoma | 2 | 2017 | 20 | 0.160 |
Why?
|
| Diverticulitis, Colonic | 1 | 2000 | 138 | 0.160 |
Why?
|
| Appendicitis | 2 | 2008 | 674 | 0.160 |
Why?
|
| Esophageal and Gastric Varices | 2 | 2011 | 208 | 0.160 |
Why?
|
| Abdominal Neoplasms | 1 | 2000 | 286 | 0.160 |
Why?
|
| Databases, Factual | 10 | 2021 | 8035 | 0.160 |
Why?
|
| Radiotherapy | 3 | 2019 | 1504 | 0.160 |
Why?
|
| Pyrazoles | 1 | 2009 | 1999 | 0.160 |
Why?
|
| Vascular System Injuries | 1 | 2022 | 247 | 0.150 |
Why?
|
| Competency-Based Education | 2 | 2017 | 218 | 0.150 |
Why?
|
| Radiotherapy, Adjuvant | 9 | 2010 | 1791 | 0.150 |
Why?
|
| Organizational Objectives | 2 | 2020 | 428 | 0.150 |
Why?
|
| Drug Utilization Review | 1 | 2019 | 251 | 0.150 |
Why?
|
| Leiomyosarcoma | 1 | 2002 | 424 | 0.150 |
Why?
|
| Postoperative Care | 7 | 2023 | 1479 | 0.150 |
Why?
|
| Advisory Committees | 2 | 2019 | 788 | 0.150 |
Why?
|
| Interleukin-6 | 5 | 2009 | 3215 | 0.150 |
Why?
|
| Videoconferencing | 1 | 2020 | 203 | 0.150 |
Why?
|
| Hypophosphatemia | 1 | 2018 | 93 | 0.150 |
Why?
|
| Physician-Patient Relations | 3 | 2020 | 3242 | 0.150 |
Why?
|
| Critical Care | 4 | 2020 | 2699 | 0.150 |
Why?
|
| Gallbladder Emptying | 2 | 1995 | 14 | 0.150 |
Why?
|
| Quinolones | 1 | 2021 | 377 | 0.150 |
Why?
|
| MAP Kinase Kinase 4 | 3 | 2007 | 149 | 0.150 |
Why?
|
| Efficiency | 2 | 2022 | 477 | 0.150 |
Why?
|
| Bile Pigments | 3 | 1994 | 13 | 0.150 |
Why?
|
| Communication | 3 | 2023 | 3849 | 0.150 |
Why?
|
| California | 5 | 2021 | 1416 | 0.150 |
Why?
|
| History, 18th Century | 1 | 2018 | 207 | 0.150 |
Why?
|
| Losartan | 1 | 2019 | 265 | 0.150 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 250 | 0.140 |
Why?
|
| Disulfiram | 1 | 2017 | 63 | 0.140 |
Why?
|
| Splanchnic Nerves | 2 | 1995 | 16 | 0.140 |
Why?
|
| Preoperative Period | 3 | 2022 | 555 | 0.140 |
Why?
|
| Postoperative Period | 4 | 2020 | 1818 | 0.140 |
Why?
|
| History, 19th Century | 2 | 2018 | 720 | 0.140 |
Why?
|
| Cholecystostomy | 1 | 2017 | 48 | 0.140 |
Why?
|
| Ambulatory Surgical Procedures | 2 | 1999 | 465 | 0.140 |
Why?
|
| Thyroidectomy | 2 | 2001 | 902 | 0.140 |
Why?
|
| Animals | 54 | 2023 | 167963 | 0.140 |
Why?
|
| Venous Thrombosis | 2 | 2020 | 1299 | 0.140 |
Why?
|
| Fellowships and Scholarships | 2 | 2010 | 1116 | 0.140 |
Why?
|
| Infection Control | 2 | 2021 | 983 | 0.140 |
Why?
|
| Antibiotic Prophylaxis | 2 | 2016 | 643 | 0.140 |
Why?
|
| Tumor Burden | 4 | 2017 | 1895 | 0.140 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 3 | 2011 | 886 | 0.140 |
Why?
|
| Guideline Adherence | 2 | 2019 | 2283 | 0.140 |
Why?
|
| Grief | 1 | 2019 | 254 | 0.140 |
Why?
|
| Angiotensins | 1 | 2017 | 143 | 0.140 |
Why?
|
| Erythromycin | 2 | 1993 | 117 | 0.140 |
Why?
|
| Taurodeoxycholic Acid | 4 | 1985 | 13 | 0.140 |
Why?
|
| Chylous Ascites | 1 | 2016 | 21 | 0.140 |
Why?
|
| Needs Assessment | 2 | 2020 | 1139 | 0.140 |
Why?
|
| Aortic Rupture | 1 | 2019 | 317 | 0.140 |
Why?
|
| Health Services Accessibility | 3 | 2021 | 5397 | 0.130 |
Why?
|
| Cholecystitis, Acute | 1 | 2017 | 74 | 0.130 |
Why?
|
| Radiography, Interventional | 3 | 2018 | 1114 | 0.130 |
Why?
|
| Cysts | 1 | 2021 | 683 | 0.130 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2019 | 582 | 0.130 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2004 | 1008 | 0.130 |
Why?
|
| Muscle, Smooth | 2 | 2006 | 924 | 0.130 |
Why?
|
| Reoperation | 9 | 2021 | 4291 | 0.130 |
Why?
|
| Reperfusion Injury | 3 | 2007 | 1023 | 0.130 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2020 | 829 | 0.130 |
Why?
|
| Liver Diseases | 3 | 2000 | 1302 | 0.130 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2018 | 167 | 0.130 |
Why?
|
| Pepsin A | 3 | 1985 | 66 | 0.130 |
Why?
|
| Mitotic Index | 1 | 2016 | 161 | 0.130 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2015 | 4048 | 0.130 |
Why?
|
| Water | 1 | 2022 | 1407 | 0.130 |
Why?
|
| Maryland | 6 | 2017 | 275 | 0.130 |
Why?
|
| Job Satisfaction | 1 | 2020 | 539 | 0.130 |
Why?
|
| Myocardial Reperfusion Injury | 3 | 2008 | 479 | 0.130 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 2 | 2006 | 257 | 0.130 |
Why?
|
| Health Care Reform | 2 | 2015 | 1245 | 0.130 |
Why?
|
| Consensus | 4 | 2021 | 3113 | 0.130 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 2015 | 66 | 0.130 |
Why?
|
| Trypsin | 4 | 1985 | 496 | 0.130 |
Why?
|
| Gastrointestinal Hormones | 1 | 1996 | 101 | 0.130 |
Why?
|
| Travel | 1 | 2021 | 785 | 0.130 |
Why?
|
| Amylases | 1 | 2015 | 169 | 0.130 |
Why?
|
| Cause of Death | 4 | 2020 | 3725 | 0.130 |
Why?
|
| Clinical Protocols | 2 | 2020 | 1440 | 0.120 |
Why?
|
| Carcinoma, Islet Cell | 2 | 2006 | 21 | 0.120 |
Why?
|
| Enteroendocrine Cells | 1 | 2016 | 77 | 0.120 |
Why?
|
| Severity of Illness Index | 7 | 2019 | 15840 | 0.120 |
Why?
|
| Anastomotic Leak | 1 | 2016 | 163 | 0.120 |
Why?
|
| Limb Salvage | 1 | 2018 | 465 | 0.120 |
Why?
|
| Fluid Therapy | 1 | 2019 | 579 | 0.120 |
Why?
|
| Phosphates | 1 | 2018 | 772 | 0.120 |
Why?
|
| Ultrasonography | 8 | 2008 | 5961 | 0.120 |
Why?
|
| Jaundice | 4 | 2015 | 97 | 0.120 |
Why?
|
| Feasibility Studies | 2 | 2023 | 5201 | 0.120 |
Why?
|
| Gastroenterostomy | 1 | 2014 | 18 | 0.120 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2018 | 515 | 0.120 |
Why?
|
| Adolescent | 29 | 2023 | 87810 | 0.120 |
Why?
|
| Gallstones | 5 | 2000 | 283 | 0.120 |
Why?
|
| Deoxycholic Acid | 2 | 1985 | 53 | 0.120 |
Why?
|
| Progesterone | 1 | 1999 | 742 | 0.120 |
Why?
|
| Hospitals | 5 | 2021 | 3928 | 0.120 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2018 | 791 | 0.120 |
Why?
|
| ROC Curve | 6 | 2019 | 3568 | 0.120 |
Why?
|
| Liver Regeneration | 1 | 2016 | 213 | 0.120 |
Why?
|
| Surgical Stapling | 1 | 2015 | 98 | 0.120 |
Why?
|
| Catheter Ablation | 3 | 2019 | 2758 | 0.120 |
Why?
|
| Peer Group | 1 | 2019 | 674 | 0.120 |
Why?
|
| Paraffin Embedding | 1 | 2015 | 302 | 0.120 |
Why?
|
| Tissue Fixation | 1 | 2015 | 241 | 0.120 |
Why?
|
| Image Enhancement | 1 | 2005 | 2881 | 0.120 |
Why?
|
| Hysterectomy | 1 | 2020 | 904 | 0.120 |
Why?
|
| Congresses as Topic | 2 | 2016 | 805 | 0.120 |
Why?
|
| Ethanol | 2 | 1998 | 1323 | 0.120 |
Why?
|
| Deglutition Disorders | 1 | 2000 | 626 | 0.120 |
Why?
|
| Video Recording | 1 | 2019 | 955 | 0.120 |
Why?
|
| Terminal Care | 2 | 2018 | 1758 | 0.120 |
Why?
|
| Contrast Media | 2 | 2005 | 5305 | 0.120 |
Why?
|
| Immunohistochemistry | 10 | 2019 | 11071 | 0.120 |
Why?
|
| Vasoconstriction | 2 | 2007 | 593 | 0.110 |
Why?
|
| Europe | 5 | 2023 | 3441 | 0.110 |
Why?
|
| Albumins | 2 | 2014 | 575 | 0.110 |
Why?
|
| Medicine | 1 | 2022 | 943 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2007 | 3484 | 0.110 |
Why?
|
| Sex Characteristics | 4 | 2008 | 2629 | 0.110 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2019 | 730 | 0.110 |
Why?
|
| Mass Screening | 2 | 2019 | 5423 | 0.110 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2022 | 1004 | 0.110 |
Why?
|
| Choice Behavior | 1 | 2020 | 821 | 0.110 |
Why?
|
| Health Planning Guidelines | 1 | 2014 | 151 | 0.110 |
Why?
|
| Research Support as Topic | 1 | 2018 | 699 | 0.110 |
Why?
|
| Pancreatic Juice | 2 | 2012 | 60 | 0.110 |
Why?
|
| Self Concept | 1 | 2020 | 1039 | 0.110 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 3 | 2007 | 498 | 0.110 |
Why?
|
| Sympathectomy, Chemical | 1 | 1993 | 25 | 0.110 |
Why?
|
| Learning Curve | 1 | 2015 | 231 | 0.110 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2016 | 1728 | 0.110 |
Why?
|
| Perioperative Care | 3 | 2016 | 1037 | 0.110 |
Why?
|
| Young Adult | 18 | 2020 | 58741 | 0.110 |
Why?
|
| Liver Abscess | 3 | 2000 | 81 | 0.110 |
Why?
|
| Patient Selection | 8 | 2016 | 4283 | 0.110 |
Why?
|
| Epithelium | 2 | 2016 | 1605 | 0.110 |
Why?
|
| Digestive System Neoplasms | 3 | 2006 | 81 | 0.110 |
Why?
|
| Barrett Esophagus | 1 | 1997 | 490 | 0.110 |
Why?
|
| Visual Acuity | 1 | 2023 | 2643 | 0.110 |
Why?
|
| Hernia, Inguinal | 2 | 2010 | 220 | 0.110 |
Why?
|
| Chenodeoxycholic Acid | 2 | 1983 | 34 | 0.110 |
Why?
|
| Bile Acids and Salts | 7 | 1994 | 382 | 0.110 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 1996 | 412 | 0.110 |
Why?
|
| Taurochenodeoxycholic Acid | 2 | 1983 | 35 | 0.110 |
Why?
|
| Pain Measurement | 3 | 2019 | 3528 | 0.110 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2006 | 184 | 0.110 |
Why?
|
| Professional Role | 1 | 2015 | 310 | 0.110 |
Why?
|
| Anesthesiology | 1 | 2023 | 1116 | 0.110 |
Why?
|
| Device Removal | 3 | 2015 | 636 | 0.100 |
Why?
|
| Biliary Tract | 2 | 1995 | 135 | 0.100 |
Why?
|
| Medical Staff, Hospital | 2 | 2015 | 600 | 0.100 |
Why?
|
| Social Behavior | 1 | 2019 | 1131 | 0.100 |
Why?
|
| Cancer Vaccines | 3 | 2011 | 1046 | 0.100 |
Why?
|
| Lymphoma | 3 | 2017 | 1898 | 0.100 |
Why?
|
| Case-Control Studies | 12 | 2017 | 22053 | 0.100 |
Why?
|
| Blood Vessels | 1 | 2018 | 1112 | 0.100 |
Why?
|
| Students, Medical | 3 | 2001 | 1927 | 0.100 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 1994 | 265 | 0.100 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2001 | 1066 | 0.100 |
Why?
|
| Survivors | 4 | 2021 | 2375 | 0.100 |
Why?
|
| Esophagitis, Peptic | 2 | 1983 | 76 | 0.100 |
Why?
|
| Cholesterol, Dietary | 4 | 1997 | 223 | 0.100 |
Why?
|
| Esophagus | 5 | 1988 | 1023 | 0.100 |
Why?
|
| In Situ Hybridization | 2 | 2014 | 1900 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 11 | 2015 | 36290 | 0.100 |
Why?
|
| Mesenchymal Stem Cells | 3 | 2007 | 1634 | 0.100 |
Why?
|
| Hospice Care | 1 | 2019 | 692 | 0.100 |
Why?
|
| Gastroparesis | 1 | 2014 | 137 | 0.100 |
Why?
|
| Hypercalcemia | 1 | 1995 | 421 | 0.100 |
Why?
|
| Patient Preference | 2 | 2019 | 922 | 0.100 |
Why?
|
| Friends | 1 | 2013 | 150 | 0.100 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2016 | 487 | 0.100 |
Why?
|
| Splenic Vein | 1 | 2011 | 30 | 0.100 |
Why?
|
| Sepsis | 5 | 2019 | 2592 | 0.100 |
Why?
|
| Choledochal Cyst | 2 | 2010 | 25 | 0.100 |
Why?
|
| Celiac Plexus | 1 | 2011 | 28 | 0.100 |
Why?
|
| History, 21st Century | 4 | 2020 | 1575 | 0.100 |
Why?
|
| Information Dissemination | 1 | 2020 | 1131 | 0.100 |
Why?
|
| Heart Arrest | 1 | 2022 | 1506 | 0.100 |
Why?
|
| Glucuronates | 1 | 1991 | 40 | 0.100 |
Why?
|
| Health Plan Implementation | 1 | 2014 | 335 | 0.100 |
Why?
|
| Music Therapy | 1 | 2013 | 110 | 0.100 |
Why?
|
| Feedback | 1 | 2015 | 791 | 0.100 |
Why?
|
| Carcinoma in Situ | 3 | 2013 | 796 | 0.100 |
Why?
|
| Advance Care Planning | 1 | 2019 | 697 | 0.100 |
Why?
|
| Hydrogen-Ion Concentration | 12 | 1995 | 2502 | 0.100 |
Why?
|
| Disclosure | 1 | 2017 | 738 | 0.090 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2006 | 1055 | 0.090 |
Why?
|
| Dexamethasone | 1 | 2018 | 1927 | 0.090 |
Why?
|
| Antibodies | 1 | 2019 | 2421 | 0.090 |
Why?
|
| Carbohydrates | 2 | 2023 | 388 | 0.090 |
Why?
|
| Radiography | 10 | 2018 | 6965 | 0.090 |
Why?
|
| Recurrence | 5 | 2017 | 8482 | 0.090 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2014 | 385 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2009 | 4357 | 0.090 |
Why?
|
| Age Factors | 8 | 2023 | 18416 | 0.090 |
Why?
|
| Disease Progression | 7 | 2022 | 13502 | 0.090 |
Why?
|
| Insurance, Health | 3 | 2021 | 2501 | 0.090 |
Why?
|
| Informed Consent | 1 | 2017 | 1005 | 0.090 |
Why?
|
| Terminology as Topic | 1 | 2018 | 1535 | 0.090 |
Why?
|
| Obesity | 2 | 2012 | 12922 | 0.090 |
Why?
|
| Physical Fitness | 1 | 2015 | 732 | 0.090 |
Why?
|
| Portasystemic Shunt, Surgical | 1 | 1990 | 39 | 0.090 |
Why?
|
| Colon | 4 | 2000 | 1788 | 0.090 |
Why?
|
| Intestinal Neoplasms | 2 | 2005 | 311 | 0.090 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2017 | 936 | 0.090 |
Why?
|
| Neoplasm Metastasis | 6 | 2020 | 4902 | 0.090 |
Why?
|
| Linear Models | 4 | 2017 | 5877 | 0.090 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2019 | 1223 | 0.090 |
Why?
|
| Medical Staff Privileges | 1 | 2009 | 15 | 0.090 |
Why?
|
| Photons | 1 | 2013 | 581 | 0.090 |
Why?
|
| Duodenal Diseases | 2 | 2003 | 99 | 0.080 |
Why?
|
| Neoplasms | 4 | 2022 | 22072 | 0.080 |
Why?
|
| ras Proteins | 1 | 2015 | 1052 | 0.080 |
Why?
|
| Surgery, Plastic | 1 | 2016 | 643 | 0.080 |
Why?
|
| Epithelial Cells | 2 | 2015 | 3663 | 0.080 |
Why?
|
| Probability | 4 | 2005 | 2475 | 0.080 |
Why?
|
| Students | 1 | 2019 | 1730 | 0.080 |
Why?
|
| Reproducibility of Results | 7 | 2020 | 20080 | 0.080 |
Why?
|
| Ulcer | 1 | 2010 | 204 | 0.080 |
Why?
|
| Barium Radioisotopes | 1 | 2008 | 1 | 0.080 |
Why?
|
| Thrombosis | 1 | 2023 | 3052 | 0.080 |
Why?
|
| Referral and Consultation | 2 | 2024 | 3598 | 0.080 |
Why?
|
| Watchful Waiting | 1 | 2013 | 510 | 0.080 |
Why?
|
| Cooperative Behavior | 1 | 2016 | 1500 | 0.080 |
Why?
|
| Intensive Care Units | 2 | 2019 | 3736 | 0.080 |
Why?
|
| Body Water | 1 | 1990 | 341 | 0.080 |
Why?
|
| Patient Compliance | 1 | 2019 | 2688 | 0.080 |
Why?
|
| Cell Line, Tumor | 7 | 2020 | 16939 | 0.080 |
Why?
|
| Arginine | 1 | 1993 | 934 | 0.080 |
Why?
|
| Body Composition | 1 | 2018 | 2419 | 0.080 |
Why?
|
| Glucocorticoids | 1 | 2018 | 2145 | 0.080 |
Why?
|
| Program Development | 3 | 2024 | 1297 | 0.080 |
Why?
|
| Mucous Membrane | 5 | 2007 | 657 | 0.080 |
Why?
|
| Barium | 1 | 2008 | 62 | 0.080 |
Why?
|
| Paracrine Communication | 2 | 2007 | 277 | 0.080 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2015 | 1355 | 0.080 |
Why?
|
| Credentialing | 1 | 2009 | 115 | 0.080 |
Why?
|
| Crohn Disease | 3 | 2000 | 2275 | 0.080 |
Why?
|
| Interpersonal Relations | 1 | 2016 | 1428 | 0.080 |
Why?
|
| Retroperitoneal Space | 4 | 2005 | 173 | 0.080 |
Why?
|
| Bandages | 1 | 2010 | 270 | 0.080 |
Why?
|
| Sensitivity and Specificity | 6 | 2020 | 14660 | 0.080 |
Why?
|
| Artificial Intelligence | 2 | 2020 | 2557 | 0.080 |
Why?
|
| Telomere | 2 | 2006 | 933 | 0.080 |
Why?
|
| Duodenostomy | 1 | 2007 | 6 | 0.080 |
Why?
|
| Chronic Disease | 5 | 2016 | 9287 | 0.080 |
Why?
|
| Bupivacaine | 1 | 2011 | 413 | 0.080 |
Why?
|
| Mice, Obese | 1 | 2009 | 420 | 0.080 |
Why?
|
| Logistic Models | 6 | 2018 | 13314 | 0.080 |
Why?
|
| Caffeine | 2 | 1989 | 702 | 0.080 |
Why?
|
| Abdominal Abscess | 2 | 2018 | 152 | 0.080 |
Why?
|
| Digestive System Abnormalities | 1 | 2008 | 49 | 0.070 |
Why?
|
| Surgical Mesh | 1 | 2010 | 311 | 0.070 |
Why?
|
| Sphincterotomy, Endoscopic | 2 | 2006 | 44 | 0.070 |
Why?
|
| Cell Movement | 1 | 2020 | 5206 | 0.070 |
Why?
|
| Neuropeptide Y | 1 | 1988 | 191 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2011 | 10827 | 0.070 |
Why?
|
| Fluorescent Dyes | 1 | 2015 | 1913 | 0.070 |
Why?
|
| Medicare | 7 | 2021 | 6786 | 0.070 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 1996 | 1529 | 0.070 |
Why?
|
| Estrogen Receptor beta | 1 | 2008 | 168 | 0.070 |
Why?
|
| Rabbits | 9 | 1990 | 4773 | 0.070 |
Why?
|
| Sorbitol | 1 | 1987 | 56 | 0.070 |
Why?
|
| Stomach | 3 | 2004 | 694 | 0.070 |
Why?
|
| Anesthesia, General | 1 | 2014 | 1166 | 0.070 |
Why?
|
| RNA-Binding Proteins | 1 | 2016 | 1894 | 0.070 |
Why?
|
| Peptic Ulcer | 1 | 2008 | 219 | 0.070 |
Why?
|
| New York | 2 | 2021 | 875 | 0.070 |
Why?
|
| Estradiol | 1 | 1994 | 1932 | 0.070 |
Why?
|
| Italy | 2 | 2020 | 841 | 0.070 |
Why?
|
| Polystyrenes | 1 | 1987 | 104 | 0.070 |
Why?
|
| Gastric Emptying | 4 | 2013 | 243 | 0.070 |
Why?
|
| Esophagitis | 2 | 1985 | 163 | 0.070 |
Why?
|
| Organizational Culture | 2 | 2022 | 506 | 0.070 |
Why?
|
| Stromal Cells | 2 | 2021 | 1326 | 0.070 |
Why?
|
| Prosthesis Failure | 2 | 2010 | 1206 | 0.070 |
Why?
|
| Dihydrotestosterone | 1 | 2007 | 195 | 0.070 |
Why?
|
| Smad4 Protein | 2 | 2019 | 191 | 0.070 |
Why?
|
| Physicians | 2 | 2019 | 4591 | 0.070 |
Why?
|
| Venous Thromboembolism | 1 | 2019 | 1864 | 0.070 |
Why?
|
| Intestinal Secretions | 2 | 1983 | 15 | 0.070 |
Why?
|
| Deferoxamine | 1 | 2007 | 153 | 0.070 |
Why?
|
| Hernia, Ventral | 1 | 2010 | 214 | 0.070 |
Why?
|
| Chemokine CCL2 | 1 | 2009 | 605 | 0.070 |
Why?
|
| Neoplasm, Residual | 1 | 2011 | 1007 | 0.070 |
Why?
|
| Calcium Carbonate | 3 | 1995 | 62 | 0.070 |
Why?
|
| Gastric Acid | 2 | 1983 | 98 | 0.070 |
Why?
|
| Gastrointestinal Agents | 1 | 2011 | 509 | 0.070 |
Why?
|
| Adenoma | 1 | 2017 | 2148 | 0.070 |
Why?
|
| Hospitalization | 4 | 2019 | 10790 | 0.070 |
Why?
|
| Gastric Juice | 2 | 1983 | 59 | 0.070 |
Why?
|
| Critical Illness | 1 | 2019 | 2709 | 0.070 |
Why?
|
| Exonucleases | 1 | 2006 | 47 | 0.070 |
Why?
|
| Carboxymethylcellulose Sodium | 1 | 2006 | 38 | 0.070 |
Why?
|
| Dogs | 5 | 1999 | 3841 | 0.070 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2001 | 3218 | 0.070 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2006 | 173 | 0.070 |
Why?
|
| Iron Chelating Agents | 1 | 2007 | 138 | 0.070 |
Why?
|
| Mesocolon | 1 | 2005 | 8 | 0.060 |
Why?
|
| Uremia | 1 | 1987 | 201 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 7 | 2017 | 22023 | 0.060 |
Why?
|
| Recombinant Proteins | 1 | 2015 | 6538 | 0.060 |
Why?
|
| Histones | 1 | 2016 | 2583 | 0.060 |
Why?
|
| Carcinoembryonic Antigen | 4 | 2003 | 336 | 0.060 |
Why?
|
| Biopsy, Needle | 4 | 2005 | 1630 | 0.060 |
Why?
|
| Macrophages | 2 | 2019 | 5745 | 0.060 |
Why?
|
| Metaplasia | 3 | 2016 | 320 | 0.060 |
Why?
|
| Absorption | 4 | 1990 | 243 | 0.060 |
Why?
|
| Adipocytes | 1 | 2012 | 1179 | 0.060 |
Why?
|
| Actuarial Analysis | 5 | 1999 | 374 | 0.060 |
Why?
|
| Peristalsis | 3 | 1998 | 59 | 0.060 |
Why?
|
| Gastrointestinal Tract | 2 | 2012 | 830 | 0.060 |
Why?
|
| Hemoperitoneum | 2 | 2022 | 38 | 0.060 |
Why?
|
| Wounds and Injuries | 1 | 2018 | 2477 | 0.060 |
Why?
|
| Infusions, Intravenous | 3 | 1998 | 2234 | 0.060 |
Why?
|
| Nerve Block | 1 | 2011 | 688 | 0.060 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 2942 | 0.060 |
Why?
|
| Antibodies, Monoclonal | 2 | 2019 | 9185 | 0.060 |
Why?
|
| Mice | 12 | 2020 | 81208 | 0.060 |
Why?
|
| Anesthetics, Local | 1 | 2011 | 1001 | 0.060 |
Why?
|
| Radiography, Abdominal | 1 | 2008 | 532 | 0.060 |
Why?
|
| Myocardium | 2 | 2008 | 4700 | 0.060 |
Why?
|
| Electron Probe Microanalysis | 3 | 1994 | 32 | 0.060 |
Why?
|
| Neurotransmitter Agents | 1 | 1988 | 663 | 0.060 |
Why?
|
| Kidney Neoplasms | 1 | 2001 | 4312 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 4 | 2010 | 5508 | 0.060 |
Why?
|
| Propensity Score | 2 | 2023 | 1928 | 0.060 |
Why?
|
| Aneurysm, False | 1 | 2007 | 257 | 0.060 |
Why?
|
| Injections, Intravenous | 2 | 2005 | 1385 | 0.060 |
Why?
|
| Insurance Coverage | 1 | 2015 | 1939 | 0.060 |
Why?
|
| Ki-67 Antigen | 2 | 2016 | 631 | 0.060 |
Why?
|
| Celiac Artery | 1 | 2004 | 65 | 0.060 |
Why?
|
| Ion Channels | 2 | 2006 | 1043 | 0.060 |
Why?
|
| Disease Management | 1 | 2014 | 2514 | 0.060 |
Why?
|
| Esophageal Neoplasms | 3 | 2005 | 1648 | 0.060 |
Why?
|
| Dilatation | 2 | 2023 | 307 | 0.060 |
Why?
|
| Parathyroid Neoplasms | 1 | 1985 | 241 | 0.060 |
Why?
|
| Nitric Oxide | 1 | 1993 | 2141 | 0.060 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2004 | 95 | 0.060 |
Why?
|
| Random Allocation | 2 | 2017 | 2394 | 0.060 |
Why?
|
| Germany | 2 | 2020 | 873 | 0.060 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2007 | 346 | 0.060 |
Why?
|
| Rectal Neoplasms | 2 | 2005 | 1152 | 0.050 |
Why?
|
| Internationality | 2 | 2021 | 1004 | 0.050 |
Why?
|
| Intestinal Mucosa | 2 | 2007 | 3022 | 0.050 |
Why?
|
| Health Care Costs | 2 | 2012 | 3258 | 0.050 |
Why?
|
| Pressure | 4 | 1998 | 1156 | 0.050 |
Why?
|
| Research Design | 3 | 2024 | 6180 | 0.050 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2007 | 701 | 0.050 |
Why?
|
| Lithotripsy | 4 | 1994 | 142 | 0.050 |
Why?
|
| Proteins | 4 | 2012 | 6029 | 0.050 |
Why?
|
| Ventricular Function, Right | 1 | 2007 | 610 | 0.050 |
Why?
|
| Treatment Failure | 2 | 2007 | 2648 | 0.050 |
Why?
|
| Adiponectin | 1 | 2009 | 1115 | 0.050 |
Why?
|
| Decision Trees | 1 | 2005 | 506 | 0.050 |
Why?
|
| Dilatation, Pathologic | 2 | 2023 | 527 | 0.050 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2007 | 479 | 0.050 |
Why?
|
| Heart Rate | 1 | 2014 | 4179 | 0.050 |
Why?
|
| Hospital Departments | 1 | 2023 | 136 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 8515 | 0.050 |
Why?
|
| Administration, Topical | 1 | 2004 | 697 | 0.050 |
Why?
|
| Glycerides | 1 | 1982 | 67 | 0.050 |
Why?
|
| Lung Injury | 1 | 2007 | 424 | 0.050 |
Why?
|
| Middle East | 1 | 2023 | 230 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 4490 | 0.050 |
Why?
|
| Hyaluronic Acid | 1 | 2006 | 482 | 0.050 |
Why?
|
| Health Expenditures | 1 | 2015 | 2362 | 0.050 |
Why?
|
| North America | 2 | 2020 | 1284 | 0.050 |
Why?
|
| Diverticulum | 1 | 2003 | 137 | 0.050 |
Why?
|
| Adult Children | 1 | 2022 | 103 | 0.050 |
Why?
|
| Enteritis | 1 | 1983 | 162 | 0.050 |
Why?
|
| Family | 1 | 2013 | 3189 | 0.050 |
Why?
|
| Catheterization, Peripheral | 2 | 1998 | 345 | 0.050 |
Why?
|
| Hyperplasia | 2 | 2023 | 1155 | 0.050 |
Why?
|
| Colonic Neoplasms | 3 | 2005 | 2526 | 0.050 |
Why?
|
| Radiation Injuries | 2 | 2013 | 1183 | 0.050 |
Why?
|
| Fibrosis | 1 | 2009 | 2042 | 0.050 |
Why?
|
| Health Status | 1 | 2015 | 4081 | 0.050 |
Why?
|
| Cell Proliferation | 4 | 2020 | 10446 | 0.050 |
Why?
|
| Propylamines | 1 | 2022 | 161 | 0.050 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2019 | 1088 | 0.050 |
Why?
|
| Malabsorption Syndromes | 1 | 1982 | 135 | 0.050 |
Why?
|
| Child | 11 | 2017 | 79806 | 0.050 |
Why?
|
| Energy Metabolism | 1 | 2012 | 2869 | 0.050 |
Why?
|
| Solvents | 1 | 1982 | 292 | 0.050 |
Why?
|
| Incidental Findings | 3 | 2015 | 698 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2016 | 5791 | 0.050 |
Why?
|
| Costs and Cost Analysis | 2 | 2004 | 1677 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2005 | 727 | 0.050 |
Why?
|
| DNA | 1 | 2014 | 7233 | 0.050 |
Why?
|
| Analysis of Variance | 5 | 2007 | 6238 | 0.050 |
Why?
|
| Frozen Sections | 1 | 2021 | 153 | 0.050 |
Why?
|
| Chlorides | 1 | 1983 | 663 | 0.040 |
Why?
|
| Confidence Intervals | 3 | 2001 | 2932 | 0.040 |
Why?
|
| Biliopancreatic Diversion | 1 | 2000 | 15 | 0.040 |
Why?
|
| Depression | 1 | 2020 | 8044 | 0.040 |
Why?
|
| Genes, MHC Class I | 1 | 2021 | 240 | 0.040 |
Why?
|
| Down-Regulation | 2 | 2018 | 2913 | 0.040 |
Why?
|
| Lithium | 1 | 1983 | 596 | 0.040 |
Why?
|
| Occupational Exposure | 2 | 2020 | 1809 | 0.040 |
Why?
|
| Iron | 2 | 2007 | 1786 | 0.040 |
Why?
|
| Thoracotomy | 1 | 2022 | 363 | 0.040 |
Why?
|
| Curriculum | 3 | 2024 | 3718 | 0.040 |
Why?
|
| Lectins | 1 | 2002 | 484 | 0.040 |
Why?
|
| Neoplasm Proteins | 2 | 2017 | 3610 | 0.040 |
Why?
|
| Choledochostomy | 1 | 1999 | 15 | 0.040 |
Why?
|
| Barium Sulfate | 1 | 2000 | 180 | 0.040 |
Why?
|
| Educational Measurement | 2 | 2017 | 1248 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 1992 | 1544 | 0.040 |
Why?
|
| Liver Function Tests | 3 | 2007 | 524 | 0.040 |
Why?
|
| DNA, Neoplasm | 3 | 2006 | 1745 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2007 | 1484 | 0.040 |
Why?
|
| Androgens | 1 | 2007 | 1291 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2016 | 11903 | 0.040 |
Why?
|
| Single-Blind Method | 2 | 2015 | 1578 | 0.040 |
Why?
|
| Reference Values | 4 | 1999 | 4925 | 0.040 |
Why?
|
| Antigens, Neoplasm | 2 | 2011 | 1998 | 0.040 |
Why?
|
| Crystallization | 6 | 1997 | 533 | 0.040 |
Why?
|
| Sports | 1 | 2005 | 700 | 0.040 |
Why?
|
| ABO Blood-Group System | 1 | 2021 | 369 | 0.040 |
Why?
|
| Phosphorylation | 3 | 2019 | 8313 | 0.040 |
Why?
|
| Immunotherapy | 2 | 2015 | 4642 | 0.040 |
Why?
|
| Double-Blind Method | 5 | 2018 | 12427 | 0.040 |
Why?
|
| Peer Review, Health Care | 1 | 2019 | 73 | 0.040 |
Why?
|
| Benzamides | 1 | 2005 | 1369 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 3 | 1994 | 941 | 0.040 |
Why?
|
| Peritoneal Neoplasms | 1 | 2005 | 707 | 0.040 |
Why?
|
| Azithromycin | 1 | 2020 | 200 | 0.040 |
Why?
|
| Pulmonary Artery | 1 | 2007 | 1921 | 0.040 |
Why?
|
| Lectins, C-Type | 1 | 2002 | 587 | 0.040 |
Why?
|
| Bacterial Infections | 1 | 2007 | 1403 | 0.040 |
Why?
|
| Accidents, Traffic | 1 | 2004 | 814 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2016 | 11481 | 0.040 |
Why?
|
| Lung | 3 | 2007 | 9994 | 0.040 |
Why?
|
| Ritonavir | 1 | 2020 | 328 | 0.040 |
Why?
|
| Short Bowel Syndrome | 1 | 1982 | 353 | 0.040 |
Why?
|
| Proteomics | 1 | 2012 | 3817 | 0.040 |
Why?
|
| Patient Participation | 2 | 2020 | 1439 | 0.040 |
Why?
|
| DNA Methylation | 3 | 2016 | 4373 | 0.040 |
Why?
|
| Anxiety | 1 | 2013 | 4538 | 0.040 |
Why?
|
| Colonoscopy | 2 | 2010 | 1387 | 0.040 |
Why?
|
| Pesticides | 1 | 2001 | 293 | 0.040 |
Why?
|
| Chemical Precipitation | 2 | 1995 | 176 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2021 | 829 | 0.040 |
Why?
|
| Asia | 1 | 2019 | 620 | 0.040 |
Why?
|
| Enterocolitis | 1 | 1999 | 106 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2013 | 4446 | 0.040 |
Why?
|
| Peritonitis | 1 | 2000 | 369 | 0.040 |
Why?
|
| Algorithms | 3 | 2023 | 13981 | 0.040 |
Why?
|
| New York City | 1 | 2020 | 724 | 0.040 |
Why?
|
| Antacids | 1 | 2017 | 94 | 0.040 |
Why?
|
| Qualitative Research | 2 | 2021 | 2963 | 0.040 |
Why?
|
| Enzyme Replacement Therapy | 1 | 2017 | 79 | 0.040 |
Why?
|
| Calcium-Binding Proteins | 1 | 2002 | 1067 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 2019 | 1060 | 0.040 |
Why?
|
| Heart | 2 | 2007 | 4393 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 422 | 0.040 |
Why?
|
| Foreign-Body Migration | 1 | 1999 | 218 | 0.040 |
Why?
|
| Infant, Newborn | 4 | 2019 | 26181 | 0.040 |
Why?
|
| Mucin-6 | 1 | 2016 | 15 | 0.040 |
Why?
|
| Abdominal Injuries | 1 | 2000 | 359 | 0.040 |
Why?
|
| Automation | 1 | 2019 | 580 | 0.030 |
Why?
|
| Pigments, Biological | 2 | 1994 | 52 | 0.030 |
Why?
|
| Glycoproteins | 2 | 1995 | 2208 | 0.030 |
Why?
|
| Regression Analysis | 4 | 2008 | 6360 | 0.030 |
Why?
|
| Child, Preschool | 6 | 2010 | 42063 | 0.030 |
Why?
|
| Sulbactam | 1 | 2016 | 31 | 0.030 |
Why?
|
| Epidermal Cyst | 1 | 2017 | 64 | 0.030 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2000 | 662 | 0.030 |
Why?
|
| Radionuclide Imaging | 3 | 1995 | 1975 | 0.030 |
Why?
|
| Cefoxitin | 1 | 2016 | 35 | 0.030 |
Why?
|
| Hematoxylin | 1 | 2016 | 60 | 0.030 |
Why?
|
| Splenic Diseases | 1 | 2017 | 90 | 0.030 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2016 | 69 | 0.030 |
Why?
|
| Mutation | 3 | 2016 | 29932 | 0.030 |
Why?
|
| Angiography | 3 | 2007 | 1605 | 0.030 |
Why?
|
| Mucin 5AC | 1 | 2016 | 97 | 0.030 |
Why?
|
| Lung Neoplasms | 3 | 2018 | 13262 | 0.030 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 1998 | 156 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2007 | 8158 | 0.030 |
Why?
|
| Ampicillin | 1 | 2016 | 141 | 0.030 |
Why?
|
| Disease Models, Animal | 5 | 2016 | 18137 | 0.030 |
Why?
|
| Comorbidity | 3 | 2015 | 10551 | 0.030 |
Why?
|
| Evidence-Based Medicine | 2 | 2021 | 3696 | 0.030 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 427 | 0.030 |
Why?
|
| Anastomosis, Roux-en-Y | 3 | 2002 | 86 | 0.030 |
Why?
|
| Gastroesophageal Reflux | 1 | 1983 | 816 | 0.030 |
Why?
|
| Carcinoma | 3 | 2004 | 2331 | 0.030 |
Why?
|
| Socioeconomic Factors | 3 | 2017 | 7806 | 0.030 |
Why?
|
| Critical Pathways | 1 | 1999 | 475 | 0.030 |
Why?
|
| Smoking | 4 | 2023 | 9073 | 0.030 |
Why?
|
| Risk Management | 1 | 2019 | 558 | 0.030 |
Why?
|
| Efficiency, Organizational | 1 | 2020 | 697 | 0.030 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 8056 | 0.030 |
Why?
|
| Cefazolin | 1 | 2016 | 94 | 0.030 |
Why?
|
| Hypersensitivity, Delayed | 2 | 2011 | 490 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2017 | 345 | 0.030 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2005 | 2418 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2019 | 464 | 0.030 |
Why?
|
| Drug Repositioning | 1 | 2017 | 232 | 0.030 |
Why?
|
| Sclerosis | 2 | 2003 | 210 | 0.030 |
Why?
|
| Empathy | 1 | 2019 | 473 | 0.030 |
Why?
|
| Medicaid | 2 | 2020 | 2815 | 0.030 |
Why?
|
| Genes, myc | 1 | 2016 | 395 | 0.030 |
Why?
|
| Copper | 1 | 2017 | 368 | 0.030 |
Why?
|
| Immunity | 1 | 2021 | 998 | 0.030 |
Why?
|
| Metronidazole | 1 | 2016 | 231 | 0.030 |
Why?
|
| Mice, Knockout | 4 | 2016 | 14372 | 0.030 |
Why?
|
| Enterococcus faecalis | 1 | 2016 | 247 | 0.030 |
Why?
|
| SEER Program | 1 | 2020 | 1530 | 0.030 |
Why?
|
| Safety Management | 1 | 2020 | 760 | 0.030 |
Why?
|
| Palmitic Acids | 1 | 1994 | 52 | 0.030 |
Why?
|
| Spiral Cone-Beam Computed Tomography | 1 | 2015 | 34 | 0.030 |
Why?
|
| Pneumonia | 2 | 2018 | 2131 | 0.030 |
Why?
|
| International Cooperation | 2 | 2015 | 1433 | 0.030 |
Why?
|
| Filtration | 1 | 2015 | 229 | 0.030 |
Why?
|
| Cell Hypoxia | 2 | 2007 | 658 | 0.030 |
Why?
|
| Medical Records | 1 | 2000 | 1407 | 0.030 |
Why?
|
| Rats | 5 | 2007 | 23711 | 0.030 |
Why?
|
| Piperazines | 1 | 2005 | 2525 | 0.030 |
Why?
|
| Gene Expression Profiling | 2 | 2016 | 9411 | 0.030 |
Why?
|
| Necrosis | 2 | 2009 | 1612 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 1 | 2024 | 2696 | 0.030 |
Why?
|
| Entropy | 1 | 2014 | 210 | 0.030 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2016 | 453 | 0.030 |
Why?
|
| Plagiarism | 1 | 2013 | 22 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 6465 | 0.030 |
Why?
|
| Professional-Patient Relations | 1 | 2019 | 726 | 0.030 |
Why?
|
| Gender Identity | 1 | 2019 | 698 | 0.030 |
Why?
|
| Ileus | 1 | 2013 | 57 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2007 | 687 | 0.030 |
Why?
|
| Antigen-Presenting Cells | 1 | 2017 | 967 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 2014 | 0.030 |
Why?
|
| Palmitic Acid | 1 | 1994 | 149 | 0.030 |
Why?
|
| Coloring Agents | 1 | 2016 | 562 | 0.030 |
Why?
|
| Mycoses | 1 | 1997 | 387 | 0.030 |
Why?
|
| Emergency Service, Hospital | 1 | 2013 | 7818 | 0.030 |
Why?
|
| Osmolar Concentration | 2 | 1991 | 660 | 0.030 |
Why?
|
| Infant | 3 | 2008 | 36060 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2019 | 1368 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2022 | 2417 | 0.030 |
Why?
|
| Observer Variation | 1 | 2019 | 2601 | 0.030 |
Why?
|
| Myoelectric Complex, Migrating | 1 | 1993 | 13 | 0.030 |
Why?
|
| Esophagectomy | 1 | 1997 | 466 | 0.030 |
Why?
|
| Cell Communication | 1 | 2020 | 1653 | 0.030 |
Why?
|
| Clostridium Infections | 1 | 2000 | 557 | 0.030 |
Why?
|
| Surgical Flaps | 1 | 1982 | 1669 | 0.030 |
Why?
|
| Calcium Phosphates | 1 | 1994 | 171 | 0.030 |
Why?
|
| Biopsy | 4 | 2010 | 6771 | 0.030 |
Why?
|
| Universities | 1 | 1998 | 992 | 0.030 |
Why?
|
| Regeneration | 1 | 1982 | 1506 | 0.030 |
Why?
|
| Medical Futility | 1 | 2014 | 133 | 0.030 |
Why?
|
| Monitoring, Intraoperative | 1 | 2019 | 942 | 0.030 |
Why?
|
| Failure to Thrive | 1 | 2013 | 140 | 0.030 |
Why?
|
| Leg | 1 | 2018 | 1090 | 0.030 |
Why?
|
| Cultural Characteristics | 1 | 2014 | 253 | 0.030 |
Why?
|
| Gastric Outlet Obstruction | 1 | 1993 | 54 | 0.030 |
Why?
|
| Luminescent Proteins | 1 | 2015 | 835 | 0.030 |
Why?
|
| Religion and Medicine | 1 | 2014 | 160 | 0.030 |
Why?
|
| Boston | 2 | 2017 | 9280 | 0.030 |
Why?
|
| Task Performance and Analysis | 1 | 2016 | 759 | 0.030 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 1993 | 260 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2005 | 3016 | 0.030 |
Why?
|
| Occupational Diseases | 1 | 2001 | 1486 | 0.030 |
Why?
|
| Health Services Misuse | 1 | 2014 | 245 | 0.030 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 1993 | 149 | 0.030 |
Why?
|
| Muscle Contraction | 2 | 2006 | 1201 | 0.030 |
Why?
|
| Cell Line | 2 | 2022 | 15620 | 0.030 |
Why?
|
| Parasympathetic Nervous System | 1 | 1993 | 141 | 0.030 |
Why?
|
| Spectrophotometry | 1 | 1992 | 311 | 0.030 |
Why?
|
| Cytomegalovirus Infections | 1 | 1999 | 831 | 0.030 |
Why?
|
| Jejunum | 1 | 2014 | 471 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2017 | 1229 | 0.030 |
Why?
|
| Heparin | 1 | 2019 | 1652 | 0.030 |
Why?
|
| Secretin | 1 | 2012 | 57 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 3584 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 2018 | 814 | 0.020 |
Why?
|
| Collagen | 1 | 2020 | 2636 | 0.020 |
Why?
|
| Blood Pressure | 3 | 2007 | 8525 | 0.020 |
Why?
|
| Africa | 1 | 2014 | 705 | 0.020 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 1994 | 465 | 0.020 |
Why?
|
| Cost Control | 1 | 2014 | 630 | 0.020 |
Why?
|
| Injections | 2 | 2011 | 830 | 0.020 |
Why?
|
| Odds Ratio | 3 | 2017 | 9716 | 0.020 |
Why?
|
| Fish Oils | 1 | 1995 | 482 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2013 | 881 | 0.020 |
Why?
|
| Rectum | 2 | 2000 | 895 | 0.020 |
Why?
|
| Interleukin-1beta | 2 | 2008 | 998 | 0.020 |
Why?
|
| Vulnerable Populations | 1 | 2017 | 696 | 0.020 |
Why?
|
| Pain | 2 | 1998 | 5066 | 0.020 |
Why?
|
| Signal Transduction | 3 | 2016 | 23376 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2015 | 1529 | 0.020 |
Why?
|
| Hedgehog Proteins | 1 | 2016 | 769 | 0.020 |
Why?
|
| Cholic Acids | 1 | 1991 | 39 | 0.020 |
Why?
|
| Cholic Acid | 1 | 1991 | 31 | 0.020 |
Why?
|
| Surgical Instruments | 1 | 1994 | 385 | 0.020 |
Why?
|
| Population Surveillance | 3 | 2011 | 2608 | 0.020 |
Why?
|
| DNA, Mitochondrial | 1 | 2016 | 858 | 0.020 |
Why?
|
| Methods | 2 | 1996 | 1074 | 0.020 |
Why?
|
| Electrophysiology | 3 | 1983 | 1265 | 0.020 |
Why?
|
| Splenomegaly | 1 | 2011 | 189 | 0.020 |
Why?
|
| Phosphatidylcholines | 1 | 1992 | 406 | 0.020 |
Why?
|
| Gene Expression | 2 | 2019 | 7588 | 0.020 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2012 | 267 | 0.020 |
Why?
|
| Common Bile Duct | 1 | 1991 | 106 | 0.020 |
Why?
|
| Streptococcus pneumoniae | 1 | 2016 | 732 | 0.020 |
Why?
|
| False Negative Reactions | 1 | 2011 | 573 | 0.020 |
Why?
|
| Data Collection | 1 | 2000 | 3315 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2015 | 1737 | 0.020 |
Why?
|
| Uganda | 1 | 2015 | 1324 | 0.020 |
Why?
|
| Minnesota | 1 | 2010 | 340 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 2 | 2016 | 5785 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 1 | 2015 | 2057 | 0.020 |
Why?
|
| Nitric Oxide Synthase | 1 | 1993 | 908 | 0.020 |
Why?
|
| Research | 1 | 1998 | 1974 | 0.020 |
Why?
|
| Minority Groups | 1 | 2017 | 1201 | 0.020 |
Why?
|
| Verapamil | 1 | 1990 | 242 | 0.020 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2016 | 1949 | 0.020 |
Why?
|
| France | 1 | 2011 | 511 | 0.020 |
Why?
|
| Point Mutation | 1 | 2015 | 1594 | 0.020 |
Why?
|
| Sympathetic Nervous System | 1 | 2012 | 520 | 0.020 |
Why?
|
| Home Care Services | 1 | 2016 | 654 | 0.020 |
Why?
|
| Cell Separation | 1 | 2015 | 1720 | 0.020 |
Why?
|
| Orthopedic Procedures | 1 | 2019 | 1263 | 0.020 |
Why?
|
| GPI-Linked Proteins | 1 | 2011 | 468 | 0.020 |
Why?
|
| Membrane Potentials | 2 | 1982 | 1095 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2017 | 2379 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 1997 | 4024 | 0.020 |
Why?
|
| Micelles | 3 | 1994 | 192 | 0.020 |
Why?
|
| Hepatic Encephalopathy | 1 | 1990 | 144 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2006 | 7850 | 0.020 |
Why?
|
| Anesthetics | 1 | 2014 | 522 | 0.020 |
Why?
|
| Bacterial Toxins | 1 | 1994 | 931 | 0.020 |
Why?
|
| Canada | 1 | 2014 | 2128 | 0.020 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2016 | 1055 | 0.020 |
Why?
|
| Potassium | 2 | 1983 | 1313 | 0.020 |
Why?
|
| Colonic Diseases | 1 | 1990 | 200 | 0.020 |
Why?
|
| Conflict of Interest | 1 | 2013 | 549 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2006 | 2506 | 0.020 |
Why?
|
| Teaching | 1 | 2016 | 1169 | 0.020 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2016 | 1245 | 0.020 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2012 | 700 | 0.020 |
Why?
|
| Fasting | 2 | 1992 | 1603 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2012 | 987 | 0.020 |
Why?
|
| Risk | 3 | 2011 | 9631 | 0.020 |
Why?
|
| Veins | 1 | 1992 | 765 | 0.020 |
Why?
|
| Pregnancy Outcome | 1 | 2019 | 2907 | 0.020 |
Why?
|
| Cross-Sectional Studies | 4 | 2015 | 25942 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 4107 | 0.020 |
Why?
|
| Psychometrics | 1 | 2017 | 3051 | 0.020 |
Why?
|
| Staphylococcus aureus | 1 | 2016 | 1462 | 0.020 |
Why?
|
| Specimen Handling | 1 | 1992 | 707 | 0.020 |
Why?
|
| Estrogens | 1 | 1994 | 1520 | 0.020 |
Why?
|
| RNA Interference | 1 | 2016 | 2846 | 0.020 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 1999 | 2421 | 0.020 |
Why?
|
| Radiotherapy Dosage | 2 | 2007 | 2897 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 2007 | 187 | 0.020 |
Why?
|
| Rodentia | 1 | 1988 | 260 | 0.020 |
Why?
|
| Immune System | 1 | 2012 | 798 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2014 | 2435 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2019 | 3448 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2013 | 1328 | 0.020 |
Why?
|
| Ventricular Pressure | 1 | 2007 | 204 | 0.020 |
Why?
|
| Enema | 1 | 1987 | 141 | 0.020 |
Why?
|
| Perfusion | 2 | 1998 | 1376 | 0.020 |
Why?
|
| Viscera | 1 | 2007 | 138 | 0.020 |
Why?
|
| Esophagoscopy | 1 | 1988 | 390 | 0.020 |
Why?
|
| Transaminases | 1 | 2007 | 196 | 0.020 |
Why?
|
| Dietary Carbohydrates | 1 | 1991 | 892 | 0.020 |
Why?
|
| Calcium, Dietary | 1 | 1989 | 531 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2007 | 522 | 0.020 |
Why?
|
| Sex Distribution | 2 | 2005 | 2295 | 0.020 |
Why?
|
| Models, Biological | 4 | 2007 | 9467 | 0.020 |
Why?
|
| Endocarditis, Bacterial | 1 | 1990 | 445 | 0.020 |
Why?
|
| Up-Regulation | 2 | 2007 | 4122 | 0.020 |
Why?
|
| Myocardial Infarction | 1 | 2007 | 11891 | 0.020 |
Why?
|
| Reflex | 1 | 1988 | 376 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2007 | 267 | 0.020 |
Why?
|
| Lipid Metabolism | 2 | 1991 | 1902 | 0.020 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 14495 | 0.020 |
Why?
|
| Streptococcal Infections | 1 | 1990 | 617 | 0.020 |
Why?
|
| Exoribonucleases | 1 | 2006 | 96 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2012 | 1189 | 0.020 |
Why?
|
| Colectomy | 1 | 1991 | 692 | 0.020 |
Why?
|
| Educational Status | 1 | 2013 | 2515 | 0.020 |
Why?
|
| Age Distribution | 2 | 2005 | 2893 | 0.020 |
Why?
|
| Attention | 1 | 2015 | 2387 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2007 | 796 | 0.020 |
Why?
|
| Movement | 1 | 1992 | 1474 | 0.020 |
Why?
|
| Appendectomy | 1 | 2008 | 431 | 0.020 |
Why?
|
| Orchiectomy | 1 | 2007 | 470 | 0.020 |
Why?
|
| Ovariectomy | 1 | 2007 | 611 | 0.020 |
Why?
|
| 14-3-3 Proteins | 1 | 2006 | 221 | 0.020 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2006 | 127 | 0.020 |
Why?
|
| Diastole | 1 | 2007 | 788 | 0.010 |
Why?
|
| Hyperkalemia | 1 | 1987 | 231 | 0.010 |
Why?
|
| Emphysema | 1 | 2007 | 240 | 0.010 |
Why?
|
| History, Medieval | 1 | 2004 | 62 | 0.010 |
Why?
|
| Models, Immunological | 1 | 2007 | 513 | 0.010 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2007 | 616 | 0.010 |
Why?
|
| Blotting, Western | 2 | 2007 | 5039 | 0.010 |
Why?
|
| Tissue Array Analysis | 1 | 2006 | 551 | 0.010 |
Why?
|
| Suture Techniques | 1 | 2009 | 790 | 0.010 |
Why?
|
| Pylorus | 1 | 2004 | 86 | 0.010 |
Why?
|
| Secretory Rate | 1 | 1983 | 81 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2019 | 4897 | 0.010 |
Why?
|
| Colitis, Ulcerative | 2 | 1999 | 1919 | 0.010 |
Why?
|
| Protein Binding | 1 | 2016 | 9335 | 0.010 |
Why?
|
| Vaginal Fistula | 1 | 1983 | 16 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2016 | 4219 | 0.010 |
Why?
|
| Apoptosis | 2 | 2012 | 9501 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1983 | 306 | 0.010 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2007 | 316 | 0.010 |
Why?
|
| Common Bile Duct Diseases | 1 | 1983 | 36 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 1983 | 399 | 0.010 |
Why?
|
| Lithium Chloride | 1 | 1983 | 82 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2016 | 8555 | 0.010 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2007 | 326 | 0.010 |
Why?
|
| Microarray Analysis | 1 | 2006 | 747 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 9530 | 0.010 |
Why?
|
| Transfection | 1 | 2011 | 5781 | 0.010 |
Why?
|
| Myocardial Contraction | 1 | 2008 | 1516 | 0.010 |
Why?
|
| Hospital Costs | 2 | 1999 | 976 | 0.010 |
Why?
|
| Georgia | 1 | 2003 | 190 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 1995 | 4013 | 0.010 |
Why?
|
| Life Style | 1 | 1994 | 3896 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2008 | 1175 | 0.010 |
Why?
|
| Intestinal Fistula | 1 | 1983 | 143 | 0.010 |
Why?
|
| New Jersey | 1 | 2003 | 291 | 0.010 |
Why?
|
| STAT3 Transcription Factor | 1 | 2006 | 877 | 0.010 |
Why?
|
| Calcinosis | 1 | 1991 | 1476 | 0.010 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 1982 | 86 | 0.010 |
Why?
|
| Michigan | 1 | 2003 | 342 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 2 | 1995 | 1744 | 0.010 |
Why?
|
| Health Policy | 1 | 2014 | 2677 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2006 | 1173 | 0.010 |
Why?
|
| Caprylates | 1 | 1982 | 113 | 0.010 |
Why?
|
| Carcinoma, Small Cell | 1 | 1984 | 416 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2014 | 4541 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2015 | 4550 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 2007 | 18957 | 0.010 |
Why?
|
| Histamine | 1 | 1983 | 498 | 0.010 |
Why?
|
| Ketamine | 1 | 1987 | 516 | 0.010 |
Why?
|
| Genotype | 1 | 2016 | 12960 | 0.010 |
Why?
|
| Fungicides, Industrial | 1 | 2001 | 13 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1989 | 1375 | 0.010 |
Why?
|
| Abdominal Muscles | 1 | 1982 | 170 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2014 | 6414 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 1993 | 3562 | 0.010 |
Why?
|
| Phenotype | 1 | 2019 | 16546 | 0.010 |
Why?
|
| Glucose | 2 | 1983 | 4351 | 0.010 |
Why?
|
| Liability, Legal | 1 | 2002 | 210 | 0.010 |
Why?
|
| Dipyridamole | 1 | 2000 | 143 | 0.010 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2001 | 365 | 0.010 |
Why?
|
| Herbicides | 1 | 2001 | 104 | 0.010 |
Why?
|
| Urban Health | 1 | 2003 | 533 | 0.010 |
Why?
|
| Consumer Product Safety | 1 | 2001 | 123 | 0.010 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2002 | 508 | 0.010 |
Why?
|
| Perioperative Nursing | 1 | 1999 | 16 | 0.010 |
Why?
|
| Atropine | 2 | 1992 | 245 | 0.010 |
Why?
|
| Physician-Nurse Relations | 1 | 1999 | 20 | 0.010 |
Why?
|
| Mitomycin | 1 | 2000 | 262 | 0.010 |
Why?
|
| Computational Biology | 1 | 2012 | 3505 | 0.010 |
Why?
|
| Catheters, Indwelling | 1 | 2002 | 428 | 0.010 |
Why?
|
| Mediastinoscopy | 1 | 1979 | 29 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2014 | 12766 | 0.010 |
Why?
|
| Lipids | 1 | 1991 | 3336 | 0.010 |
Why?
|
| Thoracic Neoplasms | 1 | 1982 | 266 | 0.010 |
Why?
|
| Ileum | 1 | 1982 | 555 | 0.010 |
Why?
|
| Computer Simulation | 1 | 1993 | 6218 | 0.010 |
Why?
|
| Anti-Infective Agents | 1 | 2007 | 981 | 0.010 |
Why?
|
| Fetus | 1 | 2007 | 1859 | 0.010 |
Why?
|
| Insecticides | 1 | 2001 | 191 | 0.010 |
Why?
|
| Stomach Ulcer | 1 | 1999 | 123 | 0.010 |
Why?
|
| Myocarditis | 1 | 2006 | 766 | 0.010 |
Why?
|
| Vipoma | 1 | 1998 | 7 | 0.010 |
Why?
|
| Portoenterostomy, Hepatic | 1 | 1998 | 22 | 0.010 |
Why?
|
| Cadherins | 1 | 2003 | 898 | 0.010 |
Why?
|
| Glucagonoma | 1 | 1998 | 14 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2006 | 2209 | 0.010 |
Why?
|
| Bronchial Neoplasms | 1 | 1979 | 110 | 0.010 |
Why?
|
| Alloys | 1 | 1999 | 113 | 0.010 |
Why?
|
| Prevalence | 1 | 2015 | 15687 | 0.010 |
Why?
|
| Ischemia | 1 | 2007 | 1893 | 0.010 |
Why?
|
| Intubation | 1 | 1998 | 139 | 0.010 |
Why?
|
| Nuclear Family | 1 | 1999 | 313 | 0.010 |
Why?
|
| Dancing | 1 | 1979 | 102 | 0.010 |
Why?
|
| Insulinoma | 1 | 1998 | 121 | 0.010 |
Why?
|
| Cholesterol 7-alpha-Hydroxylase | 1 | 1997 | 28 | 0.010 |
Why?
|
| Diagnosis-Related Groups | 1 | 1999 | 450 | 0.010 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 1 | 1997 | 60 | 0.010 |
Why?
|
| Vincristine | 1 | 2000 | 1039 | 0.010 |
Why?
|
| Microsomes, Liver | 1 | 1997 | 173 | 0.010 |
Why?
|
| Rupture | 1 | 1999 | 443 | 0.010 |
Why?
|
| Hospital Charges | 1 | 1999 | 359 | 0.010 |
Why?
|
| Risk-Taking | 1 | 2003 | 998 | 0.010 |
Why?
|
| Lung Diseases | 1 | 2007 | 1915 | 0.010 |
Why?
|
| Pregnancy | 1 | 2019 | 29749 | 0.010 |
Why?
|
| Retreatment | 1 | 1998 | 600 | 0.010 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1998 | 618 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2001 | 1722 | 0.010 |
Why?
|
| Testosterone | 1 | 2007 | 2470 | 0.010 |
Why?
|
| Hypertension, Pulmonary | 1 | 2007 | 1570 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1982 | 1521 | 0.010 |
Why?
|
| Fingers | 1 | 1979 | 506 | 0.010 |
Why?
|
| Nursing Staff, Hospital | 1 | 1999 | 344 | 0.010 |
Why?
|
| Manometry | 1 | 1998 | 453 | 0.010 |
Why?
|
| Nausea | 1 | 1999 | 678 | 0.010 |
Why?
|
| Phylogeny | 1 | 2003 | 2775 | 0.010 |
Why?
|
| Vomiting | 1 | 1999 | 650 | 0.010 |
Why?
|
| Exercise | 1 | 2012 | 5787 | 0.010 |
Why?
|
| Biosensing Techniques | 1 | 2002 | 677 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 6131 | 0.010 |
Why?
|
| Thoracic Surgery | 1 | 1982 | 725 | 0.010 |
Why?
|
| Risk Adjustment | 1 | 1999 | 601 | 0.010 |
Why?
|
| Concanavalin A | 1 | 1995 | 190 | 0.010 |
Why?
|
| Prednisone | 1 | 2000 | 1565 | 0.010 |
Why?
|
| Postcholecystectomy Syndrome | 1 | 1994 | 3 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 4463 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2007 | 4433 | 0.010 |
Why?
|
| Colic | 1 | 1994 | 44 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 3775 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 4573 | 0.010 |
Why?
|
| Uterine Neoplasms | 1 | 1983 | 1439 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1999 | 1832 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2000 | 2221 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 6068 | 0.010 |
Why?
|
| Alcoholic Beverages | 1 | 1995 | 264 | 0.010 |
Why?
|
| Immunocompromised Host | 1 | 1999 | 857 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2011 | 10181 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2000 | 2209 | 0.010 |
Why?
|
| Demography | 1 | 1998 | 1650 | 0.010 |
Why?
|
| Phospholipases | 1 | 1992 | 76 | 0.010 |
Why?
|
| Chromatography, Affinity | 1 | 1994 | 534 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 2 | 1989 | 1628 | 0.010 |
Why?
|
| Parasympatholytics | 1 | 1992 | 89 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 1992 | 645 | 0.010 |
Why?
|
| Caseins | 1 | 1992 | 103 | 0.010 |
Why?
|
| Neutropenia | 1 | 1997 | 884 | 0.010 |
Why?
|
| Health Services Research | 1 | 1999 | 1810 | 0.010 |
Why?
|
| Cholecystography | 1 | 1991 | 42 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 1983 | 2003 | 0.010 |
Why?
|
| Laparoscopes | 1 | 1990 | 37 | 0.010 |
Why?
|
| Phospholipids | 1 | 1994 | 789 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2007 | 5643 | 0.010 |
Why?
|
| Fees and Charges | 1 | 1991 | 191 | 0.010 |
Why?
|
| Hypersensitivity | 1 | 1999 | 1155 | 0.010 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1999 | 2197 | 0.010 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2000 | 1403 | 0.010 |
Why?
|
| Streptococcus | 1 | 1990 | 198 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 1997 | 1174 | 0.010 |
Why?
|
| Esophagostomy | 1 | 1988 | 6 | 0.010 |
Why?
|
| Esophagoscopes | 1 | 1988 | 16 | 0.010 |
Why?
|
| Cicatrix | 1 | 1994 | 782 | 0.000 |
Why?
|
| Gastric Dilatation | 1 | 1988 | 4 | 0.000 |
Why?
|
| Chloralose | 1 | 1987 | 14 | 0.000 |
Why?
|
| Interviews as Topic | 1 | 1994 | 2659 | 0.000 |
Why?
|
| Anesthesia, Intravenous | 1 | 1987 | 131 | 0.000 |
Why?
|
| Ovarian Neoplasms | 1 | 1983 | 4878 | 0.000 |
Why?
|
| Vaccination | 1 | 1998 | 3361 | 0.000 |
Why?
|
| Patient Discharge | 1 | 1999 | 3476 | 0.000 |
Why?
|
| Body Mass Index | 1 | 2003 | 12914 | 0.000 |
Why?
|
| Remission Induction | 1 | 1989 | 2392 | 0.000 |
Why?
|
| Gastric Bypass | 1 | 1991 | 829 | 0.000 |
Why?
|
| Electric Conductivity | 1 | 1983 | 410 | 0.000 |
Why?
|
| Smoking Cessation | 1 | 1994 | 2064 | 0.000 |
Why?
|
| Ascites | 1 | 1983 | 338 | 0.000 |
Why?
|
| Aneurysm | 1 | 1983 | 337 | 0.000 |
Why?
|
| Finger Injuries | 1 | 1979 | 145 | 0.000 |
Why?
|
| Neck | 1 | 1979 | 731 | 0.000 |
Why?
|
| Alcoholism | 1 | 1983 | 1961 | 0.000 |
Why?
|